Name | Number of supported studies | Average coverage | |
---|---|---|---|
classical monocyte | 6 studies | 25% ± 10% | |
CD4-positive, alpha-beta T cell | 5 studies | 17% ± 2% | |
conventional dendritic cell | 4 studies | 28% ± 11% | |
B cell | 4 studies | 20% ± 7% | |
hematopoietic precursor cell | 3 studies | 21% ± 2% | |
non-classical monocyte | 3 studies | 32% ± 9% | |
natural killer cell | 3 studies | 16% ± 0% | |
myeloid cell | 3 studies | 21% ± 4% | |
epithelial cell | 3 studies | 24% ± 1% | |
pericyte | 3 studies | 16% ± 1% | |
macrophage | 3 studies | 19% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 22% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 5 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 9029.54 | 180 / 180 | 100% | 9.00 | 429 / 430 |
intestine | 100% | 5291.32 | 966 / 966 | 100% | 6.07 | 525 / 527 |
esophagus | 100% | 4126.06 | 1445 / 1445 | 99% | 5.22 | 182 / 183 |
stomach | 100% | 3626.68 | 359 / 359 | 99% | 5.90 | 284 / 286 |
lung | 100% | 8374.81 | 578 / 578 | 99% | 5.99 | 1145 / 1155 |
pancreas | 100% | 3170.35 | 328 / 328 | 99% | 6.86 | 176 / 178 |
thymus | 100% | 8569.12 | 653 / 653 | 98% | 7.76 | 595 / 605 |
bladder | 100% | 3554.14 | 21 / 21 | 98% | 4.70 | 495 / 504 |
breast | 100% | 4570.86 | 459 / 459 | 98% | 5.29 | 1097 / 1118 |
skin | 98% | 3726.62 | 1779 / 1809 | 99% | 8.87 | 469 / 472 |
prostate | 100% | 6320.15 | 245 / 245 | 97% | 5.53 | 488 / 502 |
kidney | 100% | 5299.08 | 89 / 89 | 96% | 3.69 | 867 / 901 |
adrenal gland | 100% | 5635.12 | 258 / 258 | 96% | 6.33 | 220 / 230 |
uterus | 100% | 5299.30 | 170 / 170 | 94% | 3.94 | 432 / 459 |
brain | 94% | 2935.11 | 2473 / 2642 | 99% | 4.99 | 697 / 705 |
liver | 100% | 2700.03 | 226 / 226 | 84% | 2.51 | 341 / 406 |
eye | 0% | 0 | 0 / 0 | 100% | 7.04 | 80 / 80 |
spleen | 100% | 14194.20 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.36 | 1 / 1 |
peripheral blood | 100% | 12935.82 | 928 / 929 | 0% | 0 | 0 / 0 |
adipose | 100% | 4066.75 | 1201 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 3206.71 | 1325 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 3186.38 | 794 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 7.73 | 28 / 29 |
heart | 97% | 2671.56 | 831 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 3.61 | 42 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0034123 | Biological process | positive regulation of toll-like receptor signaling pathway |
GO_0007399 | Biological process | nervous system development |
GO_0001765 | Biological process | membrane raft assembly |
GO_0005886 | Cellular component | plasma membrane |
GO_0016605 | Cellular component | PML body |
GO_0005515 | Molecular function | protein binding |
Gene name | LRCH4 |
Protein name | Leucine-rich repeat and calponin homology domain-containing protein 4 (Leucine-rich repeat neuronal protein 4) (Leucine-rich neuronal protein) Leucine rich repeats and calponin homology domain containing 4 (Leucine-rich repeats and calponin homology (CH) domain containing 4, isoform CRA_b) |
Synonyms | LRRN4 LRN hCG_1794446 LRRN1 |
Description | FUNCTION: Accessory protein that regulates signaling by multiple TLRs, acting as a broad-spanning regulator of the innate immune response. In macrophages, binds LPS and promotes proper docking of LPS in lipid raft membrane. May be required for lipid raft maintenance. . |
Accessions | H7C5D9 ENST00000310300.11 O75427 ENST00000485554.6 |